RxDoctor Payments Data

Sang An, MD

Internal Medicine · Baltimore, MDNPI 1033437017

Payments from drug & device makers

$1,006in general payments, 2019–2025

Across 71 payments — averaging $14.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$457
  • Lilly USA, LLC$219
  • Novo Nordisk$156
  • AbbVie$46
  • Sunovion Pharmaceuticals Inc.$33
  • Johnson & Johnson$29
  • plus $66 from 4 others

What the payments were for

  • Food & beverage$99799%
  • Education$81%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,006 in reported general payments places this provider in the 70th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$178,684
Medicare patients
490
Services billed
2,823

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide66$113,496
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$77,066
JardianceEmpagliflozin61$76,823
JanuviaSitagliptin Phosphate44$56,798
TradjentaLinagliptin48$42,315
OzempicSemaglutide29$38,300
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog75$36,761
EliquisApixaban23$31,085
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr38$25,021
MounjaroTirzepatide13$18,998
Tresiba Flextouch U-100Insulin Degludec17$18,203
FarxigaDapagliflozin Propanediol12$15,367
Atorvastatin Calcium882$12,964
Breo ElliptaFluticasone/Vilanterol16$12,448
Advair HfaFluticasone Propion/Salmeterol14$9,776

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$219$132,49379 claims
Boehringer IngelheimJardiance, Tradjenta$25$119,138109 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$14$114,535120 claims
MerckJanuvia$11$56,79844 claims
Novo NordiskOzempic$156$38,30029 claims
AstraZenecaFarxiga$457$15,36712 claims
AbbVieSynthroid$46$3,23845 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →